A61K 31/713(20130101), A61K 9/127(20130101), A61K 31/675(20130101), A61K 31/7105(20130101), C12N 15/1137(20130101), C12Y 207/11013(20130101), G01N 33/57434(20130101), C12N 2310/14(20130101), G01N 2800/56(20130101), Y10T 436/25(20150115)
A method of detecting prostate tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the prostate of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-ι and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-ι, with respect to the control, indicates the presence of prostate cancer in the subject. The present invention is based upon the discovery that PKC-ι levels are elevated during prostate tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-ι. The invention also provides methods of treating prostate cancer by administering to the subject a compound that inhibits the expression of PKC-ι. The compound can be a small interfering RNA (siRNA) molecule.
Acevedo-Duncan, Mildred Enid; Win, Hla Y.; and Salup, Raoul, "Prostate carcinogenesis predictor" (2015). USF Patents. 38.
University of South Florida